There’s no cure for COPD, but treatments like medication, inhalers, and lifestyle changes can help. Experts are also looking into new treatment options like biologic medication and stem cell therapy.

Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

Early identification and treatment of patients with COPD at risk of exacerbation are crucial for better outcomes. Single-inhaler triple therapy (SITT) users showed improved exacerbation rates and ...

I’M Dr Suraj Kukadia, known as Dr Sooj, an NHS GP who has seen how life-changing COPD can be. As the colder months set in, I ...

Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

If you or someone close to you suffers from chronic shortness of breath, persistent cough, and reduced physical fitness, there is a chance it may be COPD. This is a serious lung disease affecting ...

An inhalable drug treatment for chronic obstructive pulmonary disease received FDA-approval June 26, drugmaker Verona Pharma announced. It is the first FDA-approved treatment for COPD in more than two ...

Dear Dr. Roach: After over 50 years of smoking, my wife has chronic obstructive pulmonary disease (COPD) and bad scarring of her lungs, but fortunately she doesn't have cancer. She had respiratory ...

With climate change, a recent uptick in wildfires and smog, and increased pollution worldwide, many people are concerned about the quality of their air. In Philly, a city that continues to rank ...